CagriSema
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
Definition
Novo Nordisk's investigational fixed-dose pairing of cagrilintide with semaglutide. REDEFINE 1 reported 20.4% mean weight loss at 68 weeks (22.7% on the adherent estimand) against 14.9% for semaglutide alone. An NDA is filed. The number undershot Novo's own 25% guidance while still beating semaglutide on its own, which is why coverage of it reads either way depending on who is writing.
CagriSema REDEFINE trial results →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Drugs and brands
Where the evidence lives
- CagriSema REDEFINE trial results
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers